PriceTargets.com logo

NASDAQ:BTAI - BioXcel Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $65.00
  • Forecasted Upside: 467.69 %
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$11.45 As of 05/25/2022 05:00 PM ET
▼ -0.01 (-0.09%)

This chart shows the closing price for BTAI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioXcel Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BTAI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BTAI

Analyst Price Target is $65.00
▲ +467.69% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for BioXcel Therapeutics in the last 3 months. The average price target is $65.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 467.69% upside from the last price of $11.45.

This chart shows the closing price for BTAI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 contributing investment analysts is to buy stock in BioXcel Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/30/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/28/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/29/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/27/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/25/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/23/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
4/24/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/24/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/23/2022HC WainwrightLower Price TargetBuy$134.00 ➝ $110.00Low
5/13/2022Canaccord Genuity GroupLower Price Target$84.00 ➝ $75.00High
5/10/2022Truist FinancialLower Price Target$125.00 ➝ $71.00High
4/14/2022HC WainwrightBoost Price TargetBuy$130.00 ➝ $134.00High
4/6/2022Bank of AmericaBoost Price TargetBuy$78.00 ➝ $80.00High
3/14/2022HC WainwrightLower Price TargetBuy$140.00 ➝ $130.00High
3/11/2022Canaccord Genuity GroupLower Price Target$95.00 ➝ $81.00High
2/16/2022UBS GroupLower Price TargetBuy$88.00 ➝ $25.00Low
11/15/2021The Goldman Sachs GroupDowngradeNeutral ➝ Sell$55.00 ➝ $24.00High
10/19/2021HC WainwrightReiterated RatingBuy$141.00High
9/17/2021HC WainwrightReiterated RatingBuy$140.00High
8/16/2021Berenberg BankReiterated RatingBuy$70.00High
6/28/2021HC WainwrightLower Price TargetBuy$176.00 ➝ $140.00Low
6/23/2021Truist FinancialLower Price TargetBuy$128.00 ➝ $125.00High
6/1/2021HC WainwrightBoost Price TargetBuy$170.00 ➝ $176.00High
5/11/2021HC WainwrightLower Price TargetBuy$175.00 ➝ $170.00High
4/9/2021Berenberg BankInitiated CoverageBuy$75.00Low
4/1/2021Truist FinancialLower Price Target$150.00 ➝ $127.00High
4/1/2021HC WainwrightLower Price TargetBuy$185.00 ➝ $175.00High
2/1/2021UBS GroupInitiated CoverageBuy$99.00Low
1/6/2021HC WainwrightBoost Price TargetBuy$175.00 ➝ $185.00N/A
12/28/2020Truist FinancialReiterated RatingBuyN/A
10/30/2020The Goldman Sachs GroupInitiated CoverageBuy$60.00High
9/2/2020Jefferies Financial GroupInitiated CoverageBuy$82.00 ➝ $82.00High
8/17/2020GuggenheimBoost Price TargetBuy$101.00 ➝ $122.00High
8/17/2020BMO Capital MarketsLower Price TargetOutperform$104.00 ➝ $95.00High
8/17/2020HC WainwrightLower Price TargetBuy$200.00 ➝ $175.00High
7/20/2020BMO Capital MarketsBoost Price TargetOutperform ➝ Positive$64.00 ➝ $104.00High
7/20/2020HC WainwrightBoost Price TargetBuy$120.00 ➝ $200.00High
7/13/2020Bank of AmericaBoost Price TargetBuy$53.00 ➝ $63.00High
7/6/2020HC WainwrightReiterated RatingBuy$120.00High
6/24/2020HC WainwrightReiterated RatingBuy$95.00Medium
6/11/2020HC WainwrightReiterated RatingBuy$95.00Medium
6/4/2020GuggenheimInitiated CoverageBuy$101.00High
5/13/2020HC WainwrightReiterated RatingBuy$95.00High
4/28/2020HC WainwrightReiterated RatingBuy$95.00High
4/1/2020Bank of AmericaInitiated CoverageBuy$45.00High
3/19/2020HC WainwrightReiterated RatingBuy$95.00High
3/10/2020BMO Capital MarketsBoost Price Target$26.00 ➝ $64.00High
2/5/2020HC WainwrightReiterated RatingBuy$30.00High
1/16/2020BMO Capital MarketsReiterated RatingOutperform ➝ Positive$26.00High
1/8/2020HC WainwrightReiterated RatingBuy$25.00 ➝ $30.00High
12/30/2019HC WainwrightInitiated CoverageBuy$25.00High
12/11/2019HC WainwrightReiterated RatingBuy$25.00High
11/20/2019HC WainwrightReiterated RatingBuy$25.00Medium
11/12/2019SunTrust BanksInitiated CoverageBuy$24.00High
9/18/2019BMO Capital MarketsSet Price TargetBuy$21.00Low
8/21/2019HC WainwrightSet Price TargetBuy$25.00Low
6/5/2019HC WainwrightSet Price TargetBuy$25.00Low
5/28/2019HC WainwrightSet Price TargetBuy$25.00Medium
3/26/2019HC WainwrightSet Price TargetBuy$25.00High
3/5/2019HC WainwrightSet Price TargetBuy$25.00Medium
2/5/2019HC WainwrightSet Price TargetBuy$25.00High
1/4/2019HC WainwrightReiterated RatingBuy$25.00Medium
12/12/2018HC WainwrightReiterated RatingBuy$25.00Medium
8/1/2018HC WainwrightReiterated RatingBuy$25.00Low
6/12/2018HC WainwrightReiterated RatingBuy$25.00High
5/3/2018HC WainwrightInitiated CoverageBuy$25.00High
4/2/2018BMO Capital MarketsInitiated CoverageOutperform$23.00High
4/2/2018UBS GroupInitiated CoverageBuy$18.00High
4/2/2018BarclaysInitiated CoverageOverweight ➝ Overweight$15.00High
(Data available from 5/25/2017 forward)

News Sentiment Rating

0.66 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/26/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2022
  • 4 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2022
  • 6 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
4/25/2022
  • 8 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2022

Current Sentiment

  • 8 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

BioXcel Therapeutics logo
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Read More

Today's Range

Now: $11.45
Low: $11.28
High: $11.83

50 Day Range

MA: $15.71
Low: $9.67
High: $21.99

52 Week Range

Now: $11.45
Low: $9.08
High: $39.00

Volume

444,020 shs

Average Volume

623,912 shs

Market Capitalization

$320.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

Frequently Asked Questions

What sell-side analysts currently cover shares of BioXcel Therapeutics?

The following sell-side analysts have issued reports on BioXcel Therapeutics in the last year: Bank of America Co., Berenberg Bank, Canaccord Genuity Group Inc., HC Wainwright, The Goldman Sachs Group, Inc., Truist Financial Co., and UBS Group AG.
View the latest analyst ratings for BTAI.

What is the current price target for BioXcel Therapeutics?

0 Wall Street analysts have set twelve-month price targets for BioXcel Therapeutics in the last year. Their average twelve-month price target is $65.00, suggesting a possible upside of 467.7%.
View the latest price targets for BTAI.

What is the current consensus analyst rating for BioXcel Therapeutics?

BioXcel Therapeutics currently has 1 sell rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BTAI will outperform the market and that investors should add to their positions of BioXcel Therapeutics.
View the latest ratings for BTAI.

How do I contact BioXcel Therapeutics' investor relations team?

BioXcel Therapeutics' physical mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The company's listed phone number is (475) 238-6837 and its investor relations email address is [email protected] The official website for BioXcel Therapeutics is www.bioxceltherapeutics.com. Learn More about contacing BioXcel Therapeutics investor relations.